[1] |
陆才德, 房炯泽. 肝癌肝移植研究进展[J]. 浙江医学, 2020, 42(14): 1459-1463. DOI: 10.12056/j.issn.1006-2785.2020.42.14.2019-1181.LU CD, FANG JZ. Advances in liver transplantation for liver cancer[J]. Zhejiang Med J, 2020, 42(14): 1459-1463. DOI: 10.12056/j.issn.1006-2785.2020.42.14.2019-1181.
|
[2] |
HAN Y, LIU D, LI L. PD-1/PD-L1 pathway: current researches in cancer[J]. Am J Cancer Res, 2020, 10(3): 727-742.
|
[3] |
DAI S, JIA R, ZHANG X, et al. The PD-1/PD-Ls pathway and autoimmune diseases[J]. Cell Immunol, 2014, 290(1): 72-79. DOI: 10.1016/j.cellimm.2014.05.006.
|
[4] |
潘思宇, 王志鑫, 周瀛, 等. PD-1/PD-L1信号通路在肝脏疾病中的功能及作用机制[J]. 临床肝胆病杂志, 2019, 35(3): 672-676. DOI: 10.3969/j.issn.1001-5256.2019.03.050.PAN SY, WANG ZX, ZHOU Y, et al. Function and mechanism of action of the PD-1/PD-L1 pathway in liver diseases[J]. J Clin Hepatol, 2019, 35(3): 672-676. DOI: 10.3969/j.issn.1001-5256.2019.03.050.
|
[5] |
UEKI S, CASTELLANETA A, YOSHIDA O, et al. Hepatic B7 homolog 1 expression is essential for controlling cold ischemia/reperfusion injury after mouse liver transplantation[J]. Hepatology, 2011, 54(1): 216-228. DOI: 10.1002/hep.24360.
|
[6] |
MORITA M, FUJINO M, JIANG G, et al. PD-1/B7-H1 interaction contribute to the spontaneous acceptance of mouse liver allograft[J]. Am J Transplant, 2010, 10(1): 40-46. DOI: 10.1111/j.1600-6143.2009.02859.x.
|
[7] |
LIU Z, YU X, REN W, et al. CD152 and PD-1 down-regulation on CD8 T cells is associated with human acute liver allograft rejection[J]. Transplant Proc, 2014, 46(10): 3511-3514. DOI: 10.1016/j.transproceed.2014.06.079.
|
[8] |
SHI XL, MANCHAM S, HANSEN BE, et al. Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction[J]. J Hepatol, 2016, 64(6): 1274-1282. DOI: 10.1016/j.jhep.2016.02.034.
|
[9] |
AYALA-MAR S, DONOSO-QUEZADA J, GONZÁLEZ-VALDEZ J. Clinical implications of exosomal PD-L1 in cancer immunotherapy[J]. J Immunol Res, 2021: 8839978. DOI: 10.1155/2021/8839978.
|
[10] |
LIU Y, LIU S, WU C, et al. PD-1-mediated PI3K/Akt/mTOR, Caspase 9/Caspase 3 and ERK pathways are involved in regulating the apoptosis and proliferation of CD4+ and CD8+ T cells during BVDV infection in vitro[J]. Front Immunol, 2020, 11: 467. DOI: 10.3389/fimmu.2020.00467.
|
[11] |
CHAUDHRI A, XIAO Y, KLEE AN, et al. PD-L1 binds to B7-1 only in cis on the same cell surface[J]. Cancer Immunol Res, 2018, 6(8): 921-929. DOI: 10.1158/2326-6066.CIR-17-0316.
|
[12] |
DENG R, CASSADY K, LI X, et al. B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease[J]. J Immunol, 2015, 194(2): 560-574. DOI: 10.4049/jimmunol.1402157.
|
[13] |
STATHOPOULOU C, GANGAPLARA A, MALLETT G, et al. PD-1 inhibitory receptor downregulates asparaginyl endopeptidase and maintains Foxp3 transcription factor stability in induced regulatory T cells[J]. Immunity, 2018, 49(2): 247-263. DOI: 10.1016/j.immuni.2018.05.006.
|
[14] |
CAI J, WANG D, ZHANG G, et al. The role of PD-1/PD-L1 axis in treg development and function: implications for cancer immunotherapy[J]. Onco Targets Ther, 2019, 12: 8437-8445. DOI: 10.2147/OTT.S221340.
|
[15] |
LEUNG CS, YANG KY, LI X, et al. Single-cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells[J]. Genome Med, 2018, 10(1): 71. DOI: 10.1186/s13073-018-0581-y.
|
[16] |
ONO Y, PEREZ-GUTIERREZ A, NAKAO T, et al. Graft-infiltrating PD-L1hi cross-dressed dendritic cells regulate antidonor T cell responses in mouse liver transplant tolerance[J]. Hepatology, 2018, 67(4): 1499-1515. DOI: 10.1002/hep.29529.
|
[17] |
DE TONI EN, GERBES AL. Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient[J]. Gastroenterology, 2017, 152(6): 1631-1633. DOI: 10.1053/j.gastro.2017.01.063.
|
[18] |
GASSMANN D, WEILER S, MERTENS JC, et al. Liver allograft failure after nivolumab treatment-a case report with systematic literature research[J]. Transplant Direct, 2018, 4(8): e376. DOI: 10.1097/TXD.0000000000000814.
|
[19] |
QIU J, TANG W, DU C. Immune checkpoint inhibitors in patients with recurrent hepatocellular carcinoma after liver transplantation: a case report and literature review[J]. Curr Cancer Drug Targets, 2020, 20(9): 720-727. DOI: 10.2174/1568009620666200520084415.
|
[20] |
VARKARIS A, LEWIS DW, NUGENT FW. Preserved liver transplant after PD-1 pathway inhibitor for hepatocellular carcinoma[J]. Am J Gastroenterol, 2017, 112(12): 1895-1896. DOI: 10.1038/ajg.2017.387.
|
[21] |
NORDNESS MF, HAMEL S, GODFREY CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient?[J]. Am J Transplant, 2020, 20(3): 879-883. DOI: 10.1111/ajt.15617.
|
[22] |
TABRIZIAN P, FLORMAN SS, SCHWARTZ ME. PD-1 inhibitor as bridge therapy to liver transplantation?[J]. Am J Transplant, 2020, 21(5): 1979-1980. DOI: 10.1111/ajt.16448.
|
[23] |
崔春晓, 杨柳晓, 王颖, 等. 肝癌患者肝移植术前使用PD-1抑制剂对移植后排斥反应的影响[J]. 中国临床医学, 2020, 27(3): 444-447. DOI: 10.12025/j.issn.1008-6358.2020.20201005.CUI CX, YANG LX, WANG Y, et al. The effect of PD-1 inhibitor treatment before liver transplantation on posttransplant rejection in liver cancer patients[J]. Chin J Clin Med, 2020, 27(3): 444-447. DOI: 10.12025/j.issn.1008-6358.2020.20201005.
|
[24] |
MUNKER S, DE TONI EN. Use of checkpoint inhibitors in liver transplant recipients[J]. United European Gastroenterol J, 2018, 6(7): 970-973. DOI: 10.1177/2050640618774631.
|
[25] |
DE BRUYN P, VAN GESTEL D, OST P, et al. Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?[J]. Curr Opin Oncol, 2019, 31(2): 54-64. DOI: 10.1097/CCO.0000000000000505.
|
[26] |
CHAE YK, GALVEZ C, ANKER JF, et al. Cancer immunotherapy in a neglected population: the current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients[J]. Cancer Treat Rev, 2018, 63: 116-121. DOI: 10.1016/j.ctrv.2017.12.004.
|
[27] |
FISHER J, ZEITOUNI N, FAN W, et al. Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review[J]. J Am Acad Dermatol, 2020, 82(6): 1490-1500. DOI: 10.1016/j.jaad.2019.07.005.
|
[28] |
HU B, YANG XB, SANG XT. Liver graft rejection following immune checkpoint inhibitors treatment: a review[J]. Med Oncol, 2019, 36(11): 94. DOI: 10.1007/s12032-019-1316-7.
|